Inflammation

Ali Tabatabaeyan et al. (2025) · Scientific reports

This triple-blind randomised trial with 59 adults who have rheumatoid arthritis (RA) explored whether inulin, a fermentable plant fibre found in foods such as chicory, garlic and onions, can calm the inflammation and joint symptoms of the disease. RA is an autoimmune condition in which the immune system attacks the joints, and the researchers noted that long-term steroids and anti-inflammatory drugs carry real side effects. Because gut bacteria are altered in people with RA, they asked whether a prebiotic that feeds beneficial bacteria could help as an add-on. Researchers in Isfahan, Iran, enrolled 60 patients with active RA (59 were analysed). For 8 weeks, one group took a 10 g sachet of inulin with a main meal each day, and the other took identical-looking maltodextrin sachets, all alongside their usual medicines. Staff measured blood inflammation markers (CRP and ESR), counted tender and swollen joints out of 28, rated pain and morning stiffness on 0 to 100 scales, tested grip strength, and scored disease activity (DAS-28) and everyday function with the Health Assessment Questionnaire. Inflammation fell more with inulin: CRP dropped by 11.72 mg/L while it rose slightly with placebo (p = 0.02). Tender joints fell by 8.1 versus 2.9 (p = 0.002), swollen joints by 3.5 versus 1.8 (p = 0.04), and disease activity by 1.57 points versus 0.67 (p = 0.02). Daily function and morning stiffness improved (both p = 0.02) and grip strength rose by about 27 units versus 4 (p = 0.02). ESR improved within the inulin group, but the difference from placebo was not significant after adjustment (p = 0.13), and pain scores fell in both groups without a significant gap (p = 0.11). No side effects were reported. The authors treat the findings as promising but note they did not measure gut bacteria or gut-lining permeability, so the mechanism remains unconfirmed. The trial lasted only 8 weeks, tested one inulin dose, and did not assess how much inulin participants already ate. The authors call for larger studies with different doses and with cytokine, microbiome and permeability measures.

Sophia Tsokkou et al. (2026) · International journal of molecular sciences

This systematic review pulled together seven randomized controlled trials to ask whether vitamin D, vitamin C, and vitamin E supplements affect endometriosis, a long-term inflammatory condition in which tissue like the uterine lining grows outside the uterus and affects roughly 1 in 10 women of reproductive age. Common symptoms include painful periods (dysmenorrhea), chronic pelvic pain, pain during intercourse (dyspareunia), and difficulty conceiving. The vitamins were chosen because vitamin D helps regulate immune signaling, while vitamins C and E act as antioxidants that neutralize reactive oxygen species (unstable molecules that damage cells and add to inflammation). Both processes are central to how endometriosis develops and causes pain. The authors registered their protocol in PROSPERO and searched PubMed, Scopus, and ScienceDirect, screening 5,639 records down to seven eligible trials. Two reviewers screened independently, and trial quality was graded with the Jadad scale and the Cochrane RoB 2 tool. The trials varied widely: vitamin D doses ranged from 2000 IU daily to 50,000 IU weekly, vitamin C and E doses from 343 mg and 84 mg to 1000 mg and 800 IU daily, and treatment lasted from about 8 weeks to 6 months. Because of this variation, results were described narratively rather than pooled. High-dose vitamin D (50,000 IU every two weeks) cut pelvic pain scores by 1.12 points (95% CI -2.1 to -0.09; p = 0.03) and lowered hs-CRP, an inflammation marker, by 0.64 mg/L. A weekly 50,000 IU regimen lowered active β-catenin (a signaling protein linked to lesion invasion) in endometrial tissue. Lower daily doses did not clearly beat placebo, since both groups improved by similar amounts. Vitamin C plus E for eight weeks reduced oxidative stress markers, and one trial reported pain drops of 43% for daily pelvic pain, 37% for painful periods, and 24% for painful intercourse. Pregnancy rates did not rise in the trial that measured them. Side effects were generally minor, mostly occasional digestive upset. Three trials were rated low risk of bias and four had some concerns. The authors describe vitamins as a possible well-tolerated adjunct for pain and oxidative stress, though not for fertility. The evidence base is small, with only seven trials, English-language inclusion only, very different dosing across studies, and no trial using a publicly available preregistered protocol. Few trials checked participants' baseline vitamin levels, so it remains unclear whether any benefit depends on deficiency. The authors call for larger multicenter trials with standardized doses, longer follow-up, and fertility and lesion outcomes.

Angelika Bogusz et al. (2026) · Nutrients

This randomized controlled trial of 46 women with endometriosis explored whether a fish-derived lipid supplement (a mixture of marine omega-3 fats such as EPA and DHA, plus compounds called squalene and alkylglycerols) adds anything to a Healthy Eating Plate diet. Endometriosis is a long-term, estrogen-dependent condition in which tissue similar to the uterine lining grows outside the uterus. Researchers increasingly describe it as an inflammatory condition, in which signaling proteins called cytokines (messengers that coordinate immune cells) help drive pelvic pain. Omega-3 fats are known to influence these immune pathways, but evidence in endometriosis has been limited, so the team treated the work as exploratory. Women aged 22 to 48 with confirmed endometriosis were randomly assigned to one of two groups for 12 weeks. Both groups followed an individualized Healthy Eating Plate diet with meal plans from a dietitian. One group also took the fish-derived lipid product, dosed by body weight (0.5 mL per kilogram daily). Blood and stool samples were collected before and after to measure five cytokines and fecal calprotectin (a marker of gut inflammation). Pain was rated on a 0 to 10 visual analog scale, and quality of life was scored with the 30-item Endometriosis Health Profile. The clearest signal was in IL-10, a cytokine that restrains immune activation: levels rose in the supplement group and the adjusted difference between groups was significant (about 5-fold higher; 95% CI 1.32 to 19.48; p = 0.019). Other cytokines gave mixed results, with IL-1β, TNF-α, and IL-6 landing right at the edge of significance (p = 0.050 to 0.057) and fecal calprotectin unchanged. Average pain scores dropped within the supplement group (5.0 to 4.3; p = 0.011), yet the difference between groups was not significant. A pain drop of at least 1 point was more common with the supplement (73.9% versus 34.8%; adjusted risk ratio 2.11, meaning roughly twice the likelihood). Quality-of-life scores did not differ between groups, and the paper did not report safety outcomes. The authors describe the pain and IL-10 findings as hints worth testing rather than proof of benefit, since most outcomes showed no consistent advantage over diet alone. The study was small, lasted only 12 weeks, had no placebo, relied on self-reported food records, and ran many secondary analyses without statistical correction. The supplement was also a complex mixture, so the effects cannot be pinned on omega-3 fats alone. The authors call for larger, longer trials that measure fatty acid levels in blood and examine immune cells directly.

Monika Kujawska et al. (2019) · Journal of ethnobiology and ethnomedicine

This historical review examined Bryonia alba (white bryony), a vine in the cucumber family, tracing its use across northern and central-eastern Europe from antiquity through the twentieth century. The authors, an ethnobiologist and an ethnologist, worked from written and oral sources rather than a clinical study, covering Sweden, Denmark, Germany, Poland, Belarus, Ukraine, Romania and the Balkans. White bryony's root closely resembles the root of mandrake (Mandragora officinarum), a plant with an extensive European magical and medicinal reputation; the paper's central finding is that this resemblance let bryony function as mandrake's cheaper stand-in, inheriting much of its folklore in the process. Rather than enrolling participants, the authors searched historical floras, pharmacopoeias, ethnographic monographs, and travel accounts for every mention of the plant, then sorted findings into categories: ritual and folk-belief use, food, folk and historical medicine, ethnoveterinary practice, and ornamental planting. They cross-checked, where sources allowed, whether a given account referred to B. alba or its close relative B. dioica, and separated practices documented only in printed herbals ("booklore") from those recorded as living oral tradition passed between households. Across independent sources, root preparations were repeatedly recorded for oedema (fluid swelling, called dropsy at the time), convulsions and epilepsy, intestinal worms, wounds, and rheumatic pain — a 1792 Swedish account describes juice collected from a hollowed-out root curing oedema and treating worms, convulsions and headache, while twentieth- and twenty-first-century accounts from Serbia and Kosovo describe the same root used as a purgative, diuretic and topical anti-rheumatic agent. The authors cite phytochemical literature attributing these effects to cucurbitacins (bitter plant compounds), also linked elsewhere to antitumor activity, while stating plainly that historical claims for epilepsy specifically lack sufficient supporting study. Toxicity is dose- and season-dependent: freshly harvested summer root contains the more toxic cucurbitacin I, and the berries carry a cited lethal dose of roughly 15 for a child and 40 for an adult. The authors report that medicinal use had become obsolete across Scandinavia, Germany and western Slavic regions by the twentieth century, surviving only in isolated Balkan communities in Serbia and Kosovo. The authors present this decline as an unusual case: a plant of substantial historical medicinal and magical importance that today survives mainly as an ornamental garden relic or, in North America, as an unrelated invasive weed. Because the review synthesizes historical and ethnographic records rather than testing the plant directly, it offers no controlled data on safety or effectiveness, and the authors themselves flag some recorded folklore as possibly the invention of root sellers rather than genuine tradition. Future work, the authors suggest, could extend this same source-based method to B. dioica across German-, Latin- and Celtic-speaking Europe.

Genxiang Mao et al. (2017) · International journal of environmental research and public health

This study asked whether older adults with chronic heart failure (CHF) — a serious condition where the heart struggles to pump blood effectively — might benefit from a short forest retreat. Thirty-six CHF patients aged 65 to 80 from Hangzhou, China, were split into two groups: most went on a 4-day trip to a forest park, while a smaller group stayed in an urban area, under otherwise matched conditions (food, activity, lodging). Both groups walked outdoors twice a day for about 90 minutes at a gentle, unhurried pace — safe enough that a nurse and doctor accompanied the walks — and avoided smoking, alcohol, and caffeine throughout the trip. Blood was drawn before and after to check heart-failure markers, blood vessel and hormone factors related to heart disease, inflammation, and antioxidant status, and everyone completed a standard mood questionnaire (POMS) before and after. After the forest trip, participants had a significantly lower level of BNP, a key blood marker doctors use to gauge heart-failure severity, compared with both their own starting level and the city group — whose BNP didn't change. The forest group also had lower endothelin-1 (a blood-vessel-constricting hormone linked to heart disease) and lower interleukin-6 (an inflammation marker) than the city group, along with signs of less oxidative cell damage. Mood improved significantly in the forest group too — less tension, depression, anger, and confusion — while the city group's mood stayed about the same. The forest site's air was dramatically cleaner: about 30 times more of the negative ions associated with fresher air, and a small fraction of the fine-particle pollution found in the city. These early results suggest that even a short, four-day forest trip may offer measurable benefits in people living with heart failure — studied as a complement to regular medical care, not a replacement for it. The study was small (33 people finished it) and short, tested in only one season, and can't fully separate the effect of the forest itself from other differences like travel, group size, or simply a change of routine. Larger, longer trials are needed before forest bathing becomes a standard recommendation for heart failure patients.

Aibo Li et al. (2025) · Frontiers in public health

This study tested whether spending three days in a forest could help lower blood pressure in older adults who already have essential hypertension (high blood pressure with no single identifiable cause). Thirty-six adults aged 60 to 80 with diagnosed hypertension took part: 24 went to a subtropical forest national park in China for a 3-day retreat, while 12 stayed in the city of Hangzhou following the same daily schedule, so researchers could compare the two settings directly. The forest group took part in daily gentle activities designed to immerse them in nature: eight trigrams boxing (a slow, breath-focused Qigong practice), a few hours of guided forest walking, a traditional tea ceremony, and a meditation session. Both groups ate the same meals and kept the same schedule. Before and after the trip, researchers measured blood pressure, heart rate, blood oxygen, heart-rate variability (a marker of nervous-system balance), several inflammation and stress-hormone markers in the blood, and mood using a standard questionnaire. After the trip, the forest group's blood pressure was significantly lower than the city group's, both the top number (systolic, ~134 vs. 147) and bottom number (diastolic, ~78 vs. 85). Inflammation, measured by a sensitive CRP blood test, was also significantly lower in the forest group. Heart-rate variability shifted in a pattern the researchers interpreted as a healthy autonomic-nervous-system adjustment for this population. On mood, the forest group reported significantly less tension and anxiety and significantly more energy and vitality than the city group; other mood measures trended better but weren't statistically significant. Heart rate, blood oxygen, and most other blood markers (IL-6, cortisol, oxidative-stress markers) didn't differ significantly between the groups. These results suggest a short forest retreat combining gentle nature-based activities may meaningfully help lower blood pressure, ease inflammation, and improve mood in older adults with hypertension, as a complement to standard care. Because the forest program bundled several practices together (forest walking, qigong, meditation, tea ceremony) and compared a larger forest group to a much smaller city group in a different location, it's hard to know how much came from the forest setting itself versus the other activities. The trial only lasted three days, so it can't say whether the benefits last, and larger, longer studies are needed before forest bathing becomes a standard recommendation for hypertension.

Qing Li et al. (2025) · Journal of occupational health

This randomized crossover trial studied 30 Japanese men, average age 63, who were at risk of developing chronic obstructive pulmonary disease (COPD) — a common lung condition that narrows airways and makes breathing harder over time, and one of the world's leading causes of death. Each man spent one day forest bathing (Shinrin-yoku, the Japanese practice of mindfully immersing yourself in a forest) in a cypress forest, and another day walking a similar distance through a nearby city, in random order — so each person acted as their own comparison. Both walks covered the same distance at the same gentle pace under the guidance of a certified forest therapist, and participants avoided alcohol and ate the same meals throughout the 3-day trip. Researchers measured inflammation markers and oxygen levels in the blood before and after each walk, checked blood-oxygen saturation with a fingertip sensor, and had participants complete standard questionnaires about breathing symptoms, sleep quality, mood, and fatigue. Forest bathing lowered several inflammation markers (CRP, IL-6, and α1-antitrypsin) significantly more than the city walk did, and raised blood-oxygen saturation, while the city walk produced no such oxygen improvement. COPD-related breathing symptoms dropped significantly after forest bathing but stayed about the same after the city walk. Sleep quality improved across most measures after forest bathing, and mood scores showed less anger, confusion, depression, and anxiety, with people feeling notably more energetic than after the city walk. Fatigue and physical discomfort also eased more after time in the forest. Both walks used the same amount of physical effort (confirmed by matched blood-lactate levels), meaning the extra benefits of the forest walk likely came from the forest environment itself — its cleaner air, plant-released aromatic compounds (phytoncides), and calming, multisensory setting — rather than simply from walking. In people at risk of COPD, these results suggest that spending a day in a forest, walking gently and mindfully, may ease inflammation, improve breathing-related symptoms, and boost mood and sleep more than an equivalent walk in the city. Forest bathing is not a treatment for COPD; the authors caution that diagnosed COPD calls for medical supervision and flat, easy trails. The study is small (30 men) and tested only two single days, so it can't yet say whether these benefits last with regular practice or apply to women or other age groups.

Imran Amjad et al. (2025) · PloS one

This pragmatic randomized controlled trial with 106 adults explored whether chiropractic spinal adjustments change measurable biological markers, not just how patients feel. Researchers tracked three systems: neuroplasticity (the nervous system's capacity to adapt, measured via brain-derived neurotrophic factor or BDNF — a protein that supports brain and nerve health), stress response (measured through cortisol, the body's primary stress hormone, sampled from blood, saliva, and hair), and inflammation (tracked via cytokines like IL-6 and TNF-α, signaling proteins immune cells use to coordinate the body's inflammatory response). The goal was to see whether chiropractic care's known benefits for pain and function might trace back to changes at this biological level. Pain-free adults aged 20-60 with a history of recurrent (subclinical) spinal discomfort were randomly assigned to 12 weeks of chiropractic spinal manipulation — delivered about three times weekly by a registered chiropractor — or a closely matched sham procedure with no actual spinal thrust. Eighty-eight of the 106 enrolled completed the 12-week assessment. Blood, saliva, and hair samples were analyzed via laboratory immunoassay at baseline, 12 weeks, and a 16-week follow-up. Blinding worked well: 94% of participants in both groups believed they had received real chiropractic care. After 12 weeks, the chiropractic group showed meaningfully higher blood BDNF (up 150 units, p=0.009 — a strong statistical signal this wasn't due to chance) and higher IL-6 (p<0.001) than the sham group, alongside lower TNF-α at both 12 and 16 weeks (p=0.023 and p=0.028). The researchers interpret the IL-6 rise not as harmful inflammation but as a "myokine" effect — the same kind of signal muscles release after exercise — since it appeared alongside lower TNF-α and IFN-γ, the markers more classically tied to harmful inflammation. By 16 weeks, blood cortisol and IFN-γ were lower in the chiropractic group than sham, though this reflected the sham group's levels rising over that period more than a further chiropractic effect. Markers like CRP and several immune cell counts (CD4, CD8, CD56) showed no clear group differences. Only five participants reported mild, short-lived muscle soreness; no other adverse events occurred. This is among the first studies to track chiropractic's biological effects over months rather than single sessions, offering a possible mechanism — neuroplasticity, stress-hormone, and inflammation changes — behind chiropractic's reported clinical benefits. But the effects were modest, confidence intervals were wide, and the single-site Pakistani sample of 88 completers, with over 30% dropout by 16 weeks, limits how far these findings generalize. Larger trials that connect these biomarker shifts to actual pain relief and function are the next step.

Zhiyong Long et al. (2023) · Frontiers in immunology

Whether the plant compounds often discussed for rheumatoid arthritis — turmeric, green tea, pomegranate, garlic — actually do anything is the question this meta-analysis set out to answer. This review gathered every randomized trial it could find on the question: 47 trials, nearly 3,900 people, fifteen different plant polyphenols, from Iran, China, Korea, Egypt, Japan, Brazil, India and the United States. The clearest picture came from two of them. The first is total glucosides of paeony, an extract of Chinese peony root that is a licensed prescription medicine in China. Twenty-three trials tested it — always added to standard RA drugs like methotrexate, never instead of them. Disease activity scores came down, and so did CRP, ESR and rheumatoid factor, the blood markers doctors track. The most interesting result: people taking it reported *fewer* side effects than people on the standard drugs alone. That fits how it is used clinically — it appears to soften the toll the conventional drugs take on the liver and stomach. The second is curcumin, the yellow compound in turmeric. Five trials, and the same direction: lower disease activity, lower inflammatory markers, no extra side effects. Green tea polyphenols looked promising across two trials. Saffron did not show a clear effect. Everything else — pomegranate, garlic, resveratrol, sesame, cinnamon, ginger, kudzu, cranberry, olive oil, quercetin — rests on one or two small trials apiece, which is encouraging but not yet evidence that bears weight. The honest caveat, which the authors state plainly themselves: the trials disagreed with each other a great deal, most were small, and when the researchers sliced the data by dose and duration some of the headline benefits faded. Nearly all of these were add-on studies. Nobody tested a polyphenol against methotrexate, so the evidence says nothing about replacing a prescribed medication. What it does support is turmeric and peony extract as the best-evidenced candidates, studied as additions to existing treatment rather than replacements for it.

Zeng L et al. (2022) · Frontiers in Immunology

This systematic review and meta-analysis evaluates the efficacy and safety of curcumin and Curcuma longa extract across five types of arthritis: rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and gout/hyperuricemia. Twenty-nine randomized controlled trials involving 2,396 participants were included, drawn from 11 countries. For RA (6 RCTs), curcumin significantly reduced disease activity (DAS28), ESR, CRP, and rheumatoid factor compared to controls. For OA (20 RCTs), curcumin reduced pain (VAS and WOMAC-pain), improved physical function, and decreased stiffness compared to placebo. Notably, curcumin showed comparable efficacy to NSAIDs (ibuprofen, diclofenac) with significantly fewer adverse events. For AS, a single RCT of nanocurcumin showed increased regulatory T cells and decreased IL-6. Two JIA trials found curcumin improved disease activity scores in children. Doses ranged from 120 to 1,500 mg daily for 4-36 weeks. The mechanisms of action include inhibition of NF-kB signaling, COX-2 suppression, NLRP3 inflammasome inhibition, and modulation of the RANK/RANKL/OPG system. Safety was favorable across all studies, with no serious adverse events attributed to curcumin. However, the evidence is limited by small sample sizes, short follow-up periods, high heterogeneity, and potential industry funding bias.

Pratyusha Veldhi et al. (2025) · Plants (Basel, Switzerland)

This 2023 ethnobotanical review investigated the medicinal plants native to Pike County, Eastern Kentucky, and their pharmacological benefits. The study combined a local survey with a literature review to validate the medicinal properties of 14 identified plants: Pawpaw (Asimina triloba), Beautyberry (Callicarpa americana), Pipsissewa (Chimaphila umbellata), Chicory (Cichorium intybus), Boneset (Eupatorium perfoliatum), Ghost Pipe (Monotropa uniflora), Princess Tree (Paulownia tomentosa), American Pokeweed (Phytolacca americana), Purslane (Portulaca oleracea), Sassafras (Sassafras albidum), Porcelain (Hibiscus sabdariffa), Slippery Elm (Ulmus rubra), Mullein (Verbascum thapsus), and Yellowroot (Xanthorhiza simplicissima). The survey identified various traditional uses for these plants, including nutritional benefits, insect repellent properties, and applications for conditions such as rheumatism, inflammation, and infections. For instance, Pawpaw is traditionally consumed for its nutritional value and has shown potential in modern research for anticancer and antimicrobial activities, with studies indicating its extracts inhibit the HIF-1 transcription factor, which is involved in tumor growth. Beautyberry has been noted for its insect-repelling properties and has demonstrated efficacy against MRSA infections in research settings. Pipsissewa has been traditionally used for rheumatism and has shown antifungal and anticancer properties in scientific studies. Chicory serves as a coffee substitute and has hepatoprotective and antidiabetic effects, while Boneset is recognized for its immune-boosting and anti-inflammatory properties. The findings highlight the rich ethnobotanical knowledge of the local population and the pharmacological potential of these plants. However, this review is limited by the small sample size of survey participants (n=4) and the reliance on self-reported data, which may introduce bias. Further research with larger, more diverse populations is needed to validate these findings and explore the therapeutic applications of these plants more comprehensively.

Mahendra Kumar Trivedi et al. (2024) · Neuropsychopharmacology reports

This 2023 randomized controlled trial investigated the effects of remote biofield energy therapy on cognitive and motor functions in adults with perceived neuropsychological problems. Biofield energy therapy is a non-pharmacological intervention that utilizes the energy surrounding and permeating the human body to enhance healing and well-being. The study involved 114 participants aged 20 to 55 years, who were randomly assigned to three groups: a control group, a sham control group, and a biofield intervention group. Cognitive and motor functions were assessed using the NIH Toolbox at baseline (day 0), day 90, and day 180. Results indicated that the biofield intervention group experienced significant improvements in language function (p < 0.0001), working memory (p < 0.0001), and episodic memory (p < 0.0001) scores compared to both the control and sham control groups. Additionally, significant enhancements were observed in locomotion, standing balance, dexterity, grip strength, and muscle endurance (p < 0.05 to p < 0.0001). No adverse effects were reported, suggesting that remote biofield energy therapy is a safe and effective non-invasive intervention for improving cognitive and motor functions in adults with neuropsychological impairments. However, this study had limitations, including a small sample size and the need for further research to validate these findings across diverse populations and settings. Larger randomized controlled trials are necessary to establish the efficacy and mechanisms of biofield energy therapy in clinical practice.

Shamini Jain et al. (2015) · Global advances in health and medicine

This study explores the concepts of consciousness and subtle energy within Indo-Tibetan philosophical and medical systems, aiming to enhance cross-cultural dialogue on the biofield. By examining the similarities and differences among Vedic, Jain, and Tibetan traditions, the research seeks to inform contemporary biofield science and improve understanding of health and healing practices. The integration of traditional knowledge with modern scientific methods is emphasized as a means to bridge the gap between ancient wisdom and contemporary health sciences. The study employs a descriptive analysis to investigate the relationship between ancient Indo-Tibetan systems and modern biofield science. It does not involve a specific intervention or treatment but rather focuses on the philosophical concepts related to consciousness and subtle energy. The research highlights the importance of introspective inquiry in these ancient systems, paralleling modern scientific findings in health and wellness. The objective is to foster deeper cross-cultural dialogue and enhance understanding of biofields through the exploration of these traditional concepts. The findings indicate that there are significant similarities and differences in the understanding of biofields across the three traditions studied. The authors suggest that integrating traditional diagnostic methods with contemporary biomarkers could inform treatment options and improve health outcomes. However, limitations include the need for more empirical studies to validate the proposed connections and the challenges of integrating diverse methodologies. The study aligns with previous research that has explored genetic and metabolic differences associated with traditional medicine systems, suggesting a valuable intersection between traditional and modern approaches. The implications of this research are significant for practitioners and researchers in health and healing. By incorporating holistic approaches and traditional diagnostic methods alongside modern biomarkers, practitioners may enhance health assessments and treatment options. Key limitations include the necessity for empirical validation of the proposed links and the challenges in integrating methodologies from Eastern and Western perspectives. Future research should focus on empirical investigations of biofield practices and their effects on health outcomes, particularly regarding the mechanisms of subtle energy interactions.